E-DRUG: Good Governance in Management of Medicines- online course, hosted by USAID
----------------------------------------------------------------------------
Dear E-Druggers,
The USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS)
Program is pleased to announce that the 'Good Governance in the Management
of Medicines' online course, hosted on the USAID Global Learning Center
(GHeL), is now open for you to take.
This course provides learners with an understanding of the importance of
good governance throughout the process of pharmaceutical management
(selecting, procuring, distributing, and using medicines and
other pharmaceutical products). Key interventions that can promote good
governance are discussed, as well as important considerations when working
with countries to implement improvement strategies.
Follow the link below to accesses the course and learn more:
https://www.globalhealthlearning.org/course/good-governance-management-medicines
Please share this course with your colleagues
Poor governance leaves health systems vulnerable to corrupt practices and
mismanagement. When these problems occur in pharmaceutical systems, the
ramifications can be costly for governments, institutions, and individuals.
Corruption and poor management can also diminish access to medicines and
may lead to the consumption of adulterated, ineffective, or inappropriate
products that harm patients. Good governance in the management of
medicines, vaccines, and other pharmaceutical products (called
pharmaceutical management) is an important concern for governments,
citizens, development partners, and other stakeholders.
Objectives
Upon completion of the course, the learner will be able to do the following:
1. Recall the definition of governance that is applicable to the
management of medicines and other pharmaceutical products
2. List the United Nations Development Programme (UNDP) principles of
good governance
3. Explain why pharmaceutical systems are vulnerable to corruption
4. Identify problems that can occur as a result of poor governance in
pharmaceutical systems and the potential consequences for the health system
and individuals
5. Name strategies that can promote good governance in pharmaceutical
systems
6. Discuss key considerations for assisting countries, institutions,
and staff to strengthen governance in pharmaceutical systems
7. Know where to look for further information on initiatives and
organizations working on governance issues that affect access to
and appropriate use of medicines
We look forward to seeing you online.
Kind regards,
Andrew
Andrew N. Brown PhD BPharm
Adjunct Associate Professor, University of Canberra
anbrown.hss@gmail.com